Adamis Pharmaceuticals (ADMP) recently reported their Q2 earnings that revealed a slight miss on EPS and a miss on revenue. Typically, a miss on both EPS and revenue would have a negative impact on the stock. However, the company is starting to record substantial revenue growth quarter-over-quarter and year-over-year. During the company's earnings call CEO Dr. Dennis Carlo stated in "our obstacles will turn into our success," which made me chuckle as a result of the number and size of "hurdles" in the company's past. These "hurdles" include several dilutions, CRLs, overdue partnership